Here Are Wednesday’s Best Wall Street Analyst Research Calls: Devon Energy, Flowserve, Klaviyo, Macerich, Merck, Nucor, Take-Two Interactive Software, Twilio, and More
Wall Street analyst calls for June 24, 2026 covered upgrades, downgrades, and initiations across sectors. Wells Fargo upgraded Invitation Homes to Overweight, lifting its target to $33. Citigroup raised Macerich to Buy ($28). KeyBanc increased Nucor to Overweight ($274). Downgrades included Flowserve to Hold ($70) at TD Cowen and Nuvalent to Market Perform ($124) from Bernstein.
How this was made
The 30-second read
Why it matters
For each named issuer, the only disclosed catalyst is an analyst rating change and (for most) a revised price target; there are no earnings prints, guidance updates, or operational announcements in the provided text.
Market read
Traders can use the rating/target changes for short-term positioning, but the article lacks new fundamental disclosures, limiting decision quality.
What to watch
The text omits the underlying analyst thesis for each move; traders should verify whether the PT changes reflect new data (orders, trials, guidance) or just valuation/risk adjustments.
Background
The piece is a daily Wall Street research-calls roundup alongside a broad market wrap (futures, rates, oil, gold, and crypto).
Ticker impact
Invitation Homes was upgraded to Overweight from Equal Weight at Wells Fargo, with a $33 target versus $31.
Mild positive bias for the session/next few days; follow-through depends on broader market tape.
The article discloses only the rating/target change; no earnings, guidance, or company-specific operational update is provided.
Macerich was upgraded to Buy from Neutral at Citigroup, raising its target to $28 from $24.
Short-term upward drift possible, but likely limited without additional company news.
This is a single-broker rating/target update; the text provides no new fundamentals beyond the PT change.
Nucor was raised to Overweight from Sector Weight at KeyBanc with a $274 target.
Potential modest upside bias over days as traders price the upgrade.
No thesis details or new data are included; impact is therefore mostly sentiment/positioning-driven.
Varonis Systems was upgraded to Overweight from Equal Weight at Stephens, lifting the target to $45 from $33.
Higher probability of near-term outperformance versus peers if the market is receptive.
The article provides the magnitude of the PT change but not the underlying driver/thesis.
Apogee Therapeutics was downgraded to Neutral from Outperform at Mizuho, with a $135 target.
Near-term downside pressure possible until buyers reassert; watch for any offsetting deal/news flow.
The text adds that AbbVie is buying the company at that level, which may cap downside but still signals reduced upside.
Flowserve was downgraded to Hold from Buy at TD Cowen, with a $70 target.
Mild-to-moderate negative bias over the next few sessions.
Only the rating/target change is provided; no new operational or order-book information is disclosed.
Nuvalent was cut to Market Perform from Outperform at Bernstein, slashing the target to $124 from $172.
Higher likelihood of downside or underperformance versus the broader market in the near term.
The magnitude of the PT cut is material, but the article omits the specific new evidence behind it.
Principal Financial Group was cut to Underperform from Neutral at Bank of America, trimming the target to $95 from $98.
Limited downside bias; more likely to affect relative performance than trigger a major repricing alone.
The article provides only the rating/target adjustment without new earnings or guidance.
Market effects
Mixed signals across real estate (INVH, MAC), industrials/cyclicals (NUE, FLS), and healthcare/biotech (APGE, NUVL), with no single sector-wide catalyst beyond analyst sentiment.
Primarily US single-name sentiment; broader macro tape (rates/oil/crypto sell-off) is discussed but not tied to these specific companies.
Limited; the article’s global references are macro/market wrap context rather than company-specific international developments.
Counterpoint
Because this is a multi-name analyst roundup with no new company fundamentals, the market may discount it quickly—especially if broader macro (rates/tech sell-off) dominates.
Key entities
- companyInvitation Homes
Upgraded to Overweight from Equal Weight at Wells Fargo; target $33 vs $31.
- companyMacerich
Upgraded to Buy from Neutral at Citigroup; target $28 vs $24.
- companyNucor
Raised to Overweight from Sector Weight at KeyBanc; target $274.
- companyVaronis Systems
Upgraded to Overweight from Equal Weight at Stephens; target $45 vs $33.
- companyApogee Therapeutics
Downgraded to Neutral from Outperform at Mizuho; target $135; AbbVie buying at that level is mentioned.
